Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

WHAT IF ZYESAMI (TM) TURNS OUT TO BE A COVID-19 HOME RUN??? ———— What studies follow and how fast??? Drug repurposing??? —————————

Drug repurposing is one such strategy. Many agents approved for other uses already have been tested in humans, so detailed information is available on their pharmacology, formulation and potential toxicity. Because repurposing builds upon previous research and development efforts, new candidate therapies could be ready for clinical trials quickly, speeding their review by the Food and Drug Administration and, if approved, their integration into health care. ~ NIH > NCATS. https://ncats.nih.gov/preclinical/repurpose
———————-
VIP BEYOND COVID-19, if pulmonary arterial hypertension (PAH), asthma and chronic obstructive pulmonary disease (COPD) share important pathological features, can multiple inhaled VIP clinical studies be conducted at same locations, concurrently??? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090995/
——————-
DR., WHAT SAY YOU???

The Global Asthma and COPD Drugs market is expected to reach $50,359 million by 2022, growing at a CAGR of 3.7% from 2016 to 2022. Asthma is a chronic respiratory disease blocking the airways of lung because of inflammation, mucus production, tighten of muscles. Chronic Obstructive Pulmonary Disease(COPD) is caused by obstruction in the airways causing difficulty in breathing, with the primary cause as tobacco smoking.

https://www.alliedmarketresearch.com/asthma-COPD-drug-market

The global pulmonary arterial hypertension market size was valued at USD 6.3 billion in 2019. It is expected to register a CAGR of 5.6% over the forecast period.

https://www.grandviewresearch.com/industry-analysis/pulmonary-arterial-hypertension-market